Neuroleptic Malignant Syndrome is a rare but potentially fatal condition requiring prompt recognition, withdrawal of neuroleptics, and supportive care.
Answers are grounded in this paper and cite their sources.
Clinicians must maintain vigilance for NMS with neuroleptics; review confirms features but leaves open prevention strategies.
Neuroleptic Malignant Syndrome is a disabling reaction to neuroleptic drugs recently discussed in psychiatric literature in Europe, Japan, and the United States. It is rare but potentially fatal and is more likely to occur in men, especially young men, than in women. The cause is unknown, but dopamine depletion in the brain is suspected. Treatment usually begins by withdrawing the neuroleptics and then providing supportive therapy for the usual symptoms of high fever, muscular rigidity, labile blood pressure, and tachycardia. The Neuroleptic Malignant Syndrome usually lasts two to three weeks.
No takes yet. Share an insight, caveat, or question.
John B. Murray (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: